Titan BiotechBOM:524717 -1.88%51 EBITDA Margin % is 24.20% as of Mar. 2026, which is 21% above its 10-year median of 20.05. GuruFocus rates BOM:524717 with a GF Score™ of 51/100 and a GF Value™ of ₹144.21 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 941 Biotechnology companies, Titan Biotech ranks better than 83.74% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Titan Biotech's EBITDA for the
three
months ended in Mar. 2026 was ₹118 Mil. Titan Biotech's Revenue for the
three
months ended in Mar. 2026 was ₹488 Mil. Therefore, Titan Biotech's EBITDA margin for the quarter that ended in Mar. 2026 was 24.20%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Titan Biotech EBITDA Margin % Related Terms
Titan Biotech EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Titan Biotech's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:524717 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Titan Biotech's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Titan Biotech EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Titan Biotech's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Titan Biotech's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Titan Biotech (BOM:524717) has a EBITDA Margin % of 24.20% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Titan Biotech and its competitors. This is 21% above median its historical median of 20.05. Over the past decade, Titan Biotech's EBITDA Margin % has ranged from 10.40 to 32.62. According to the industry distribution chart, Titan Biotech ranks #153 out of 941 companies in the Biotechnology industry, placing it in the top 16.3%.
Is Titan Biotech's EBITDA Margin % too high?
Titan Biotech's current EBITDA Margin % of 24.20% is 21% above median its 10-year median of 20.05. Over the past 10 years, this metric has ranged from a low of 10.40 to a high of 32.62. Based on the distribution chart, Titan Biotech ranks #153 out of 941 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Titan Biotech has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Titan Biotech's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Titan Biotech ranks #153 out of 941 companies for EBITDA Margin %. This places Titan Biotech in the top 16% of its industry — outperforming the majority of peers. Historically, Titan Biotech's own EBITDA Margin % has ranged from 10.40 to 32.62 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Titan Biotech and its competitors. Titan Biotech's current EBITDA Margin % is 24.20%, which is 21% above median its own 10-year median of 20.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Titan Biotech stock overvalued right now?
Based on GuruFocus' analysis, Titan Biotech (BOM:524717) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹144.21, compared to a current price of ₹390.40 — trading 170.7% above its estimated fair value. The current EBITDA Margin % is 24.20%, which is 21% above median its 10-year median of 20.05. Titan Biotech's overall GF Score™ is 51/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Titan Biotech (BOM:524717), the current EBITDA Margin % is 24.20% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Titan Biotech (BOM:524717) Overvalued in 2026?
Based on GuruFocus' analysis, Titan Biotech stock appears to be overvalued.
The current stock price of ₹390.40 is trading 170.7% above its estimated GF Value™ of ₹144.21.
GuruFocus considers Titan Biotech to be Significantly Overvalued.
Key valuation signals for BOM:524717:
EBITDA Margin %: 24.20% (21% above median its 10-year median of 20.05)
GF Value™: ₹144.21 vs. price of ₹390.40 (170.7% above fair value)
No single metric tells the full story. See the BOM:524717 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Titan Biotech Ltd is a manufacturer and exporter of biological products. It manufactures biological products such as peptone, malt extract, yeast extract, liver extract, bile extract, culture media, laboratory chemicals, plant growth promoters, and others. The biological products have applications in the field of pharmaceutical, nutraceutical, food and beverages, biotechnology and fermentation, cosmetic, veterinary and animal feed, agriculture industries, and others. The company's business activity falls within a single primary business segment, which is the business of Biological Products. The firm sells its products in India and also exports internationally, of which the majority of the revenue is derived from the sales made in India.
51GF Score
Get the complete analysis for BOM:524717
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524717 has been successfully added to your 
